Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.66 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.49 |
| ▸ | VEGFA | P15692 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | TET3 | O43151 | 1/20 | 0.49 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.49 |
| ▸ | ASPH | Q12797 | 1/20 | 0.49 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.49 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.49 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.49 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.49 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485871 | 0.88 | EGLN1 (0.55) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL3484936 | 0.86 | EGLN1 (0.53) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL14122489 | 0.86 | EGLN1 (0.67) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL3485009 | 0.85 | GRIN2B (0.53) | EGLN1 | |
| SCHEMBL29554406 | 0.85 | EGLN1 (0.54) | EGLN1PTGER2 | |
| SCHEMBL28730721 | 0.85 | EGLN1 (0.54) | EGLN1PTGER2 | |
| SCHEMBL14150467 | 0.83 | EGLN1 (0.50) | EGLN1EGLN3VEGFAFLT1PTGER2 | |
| SCHEMBL14150317 | 0.82 | GRIN2B (0.55) | EGLN1 | |
| SCHEMBL14150280 | 0.82 | EGLN1 (0.52) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL14150470 | 0.82 | EGLN1 (0.49) | EGLN1EGLN3VEGFAFLT1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251671-A1 | COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | Akebia Therapeutics Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2717870-B1 | COMPOSITION FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA USEFUL FOR TREATING CANCER | AKEBIA THERAPEUTICS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160199434-A1 | COMPOSITIONS AND METHODS FOR MODULATING DNA METHYLATION | OHIO STATE INNOVATION FOUNDATION (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3032953-A2 | COMPOSITIONS AND METHODS FOR MODULATING DNA METHYLATION | Ohio State Innovation Foundation (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023967-A2 | COMPOSITIONS AND METHODS FOR MODULATING DNA METHYLATION | OHIO STATE INNOVATION FOUNDATION (US) | 2015-02-19 | — | — | WO | disclosed |
| US-8865748-B2 | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer | AKEBIA THERAPEUTICS INC. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-2717870-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | Akebia Therapeutics Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120329836-A1 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | THE OHIO STATE UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012170442-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | AKEBIA THERAPEUTICS INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170439-A1 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | THE OHIO STATE UNIVERSITY (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316204-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | AKEBIA THERAPEUTICS INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199434-A1 | COMPOSITIONS AND METHODS FOR MODULATING DNA METHYLATION | MYC, MYCBP, DNMT1 | EGLN1 1848/4885EGLN3 1916/4885VEGFA 2319/4885 |
| US-20120316204-A1 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | HIF1A, HIF1AN, EGLN2 | EGLN1 5/4885EGLN3 4/4885VEGFA 418/4885 |
| US-20120329836-A1 | METHODS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | HIF1A, HIF1AN, EGLN2 | EGLN1 6/4885EGLN3 4/4885VEGFA 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.